11,12-dihydroxy-13,14-epoxy-11,12,13,14-tetrahydrodibenzo(a,l)pyrene: RN refers to (alpha,beta,beta,beta)-stereoisomer; structure in first source [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 3035186 |
| MeSH ID | M0231963 |
| Synonym |
|---|
| 11,12,12a,13a-tetrahydro- (11alpha,12abeta,13abeta)dibenzo(5,6:10,11)chryseno(3,4-b)oxirene-11,12-diol |
| syn-dibenzo(a,l)pyrene diolepoxide |
| ccris 7385 |
| syn-dibenzo(a,l)pyrene-11,12-dihydrodiol-13,14-epoxide |
| 11,12-dihydroxy-13,14-epoxy-11,12,13,14-tetrahydrodibenzo(a,l)pyrene |
| dibenzo(5,6:10,11)chryseno(3,4-b)oxirene-11,12-diol, 11,12,12a,13a-tetrahydro-, (11r,12s,12ar,13as)-rel- |
| dibenzo(5,6:10,11)chryseno(3,4-b)oxirene-11,12-diol, 11,12,12a,13a-tetrahydro- (11alpha,12abeta,13abeta)- |
| syn-11,12,12a,13a-tetrahydrodibenzo(5,6:10,11)chryseno(3,4-b)oxirene-11,12-diol |
| 153857-28-4 |
| 11,12,12a,13a-tetrahydronaphtho[4',3',2',1':1,12]tetrapheno[10,11-b]oxirene-11,12-diol |
| DTXSID60934857 |
| syn-dibenzo[a,l]pyrene-11,12-dihydrodiol-13,14-epoxide |
| 4-oxaheptacyclo[11.10.2.02,8.03,5.010,24.017,25.018,23]pentacosa-1(24),2(8),9,11,13(25),14,16,18,20,22-decaene-6,7-diol |
| (3s,5r,6s,7r)-4-oxaheptacyclo[11.10.2.02,8.03,5.010,24.017,25.018,23]pentacosa-1(24),2(8),9,11,13(25),14,16,18,20,22-decaene-6,7-diol |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (53.85) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| benzo(a)pyrene | ortho- and peri-fused polycyclic arene | carcinogenic agent; mouse metabolite | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| dibenzo(a,l)pyrene | ortho- and peri-fused polycyclic arene | human metabolite; mutagen | 1997 | 2011 | 23.8 | high | 0 | 0 | 4 | 0 | 1 | 0 | |
| 7,8-dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | epoxide | intercalator | 1995 | 2009 | 22.0 | high | 0 | 0 | 1 | 2 | 0 | 0 | |
| 1,2-epoxy-3,4-dihydroxy-1,2,3,4-tetrahydrobenzo(c)phenanthrene | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 | |||
| dibenzo(a,l)pyrene 11,12-dihydrodiol | 1994 | 1997 | 28.5 | high | 0 | 0 | 2 | 0 | 0 | 0 | |||
| benzo(g)chrysene-11,12-dihydrodiol-13,14-epoxide | 1995 | 1995 | 29.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 | |||
| thioguanine anhydrous | 2-aminopurines | anticoronaviral agent; antimetabolite; antineoplastic agent | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| phenanthrenes | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abnormalities, Autosome | 0 | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 | |
| Breast Cancer | 0 | 1997 | 1999 | 26.0 | high | 0 | 0 | 2 | 0 | 0 | 0 | |
| Breast Neoplasms | 0 | 1997 | 1999 | 26.0 | high | 0 | 0 | 2 | 0 | 0 | 0 | |
| Carcinoma | 0 | 1997 | 1997 | 27.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 | |
| Carcinoma, Anaplastic | 0 | 1997 | 1997 | 27.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 | |
| Experimental Mammary Neoplasms | 0 | 1995 | 1995 | 29.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |